Short-term investments (amortized cost of 307,394)
307,610
Prepaid expenses and other current assets
11,015
Refundable income taxes
1,793
Grants receivable
475
Cash and cash equivalents
207,820
Research and development tax credits receivable
280
Total current assets
528,993
Restricted cash
319
Other assets
898
Right of use assets
5,129
Long-term investments (amortized cost of 74,475)
74,614
Research and development tax credits receivable, net of current portion
7,955
Total assets
623,083
Other accrued expenses
796
Lease liabilities
1,516
Accrued personnel expenses
23,774
Deferred income
1,477
Accounts payable
6,249
Accrued clinical trial costs
36,462
Total current liabilities
70,274
Unrecognized tax benefits
48,790
Lease liabilities, net of current portion
3,612
Grants repayable, net of current portion
6,606
Total liabilities
129,282
Accumulated deficit
-123,123
Common stock, 0.001 par value 150,000,000 shares authorized at march 31, 2025 and december 31, 2024 38,271,682 and 36,598,043 shares issued and outstanding, respectively
44
Additional paid-in capital
633,070
Accumulated other comprehensive loss
-16,190
Total stockholders equity
493,801
Total liabilities and stockholders equity
623,083
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.